JP2008542296A - サーチュイン活性化剤による眼障害の処置 - Google Patents

サーチュイン活性化剤による眼障害の処置 Download PDF

Info

Publication number
JP2008542296A
JP2008542296A JP2008513752A JP2008513752A JP2008542296A JP 2008542296 A JP2008542296 A JP 2008542296A JP 2008513752 A JP2008513752 A JP 2008513752A JP 2008513752 A JP2008513752 A JP 2008513752A JP 2008542296 A JP2008542296 A JP 2008542296A
Authority
JP
Japan
Prior art keywords
formula
compound
further embodiment
attendant definitions
sirtuin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008513752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008542296A5 (enExample
Inventor
マイケル ミルバーン，
クリストフ エイチ． ウェストファール，
デイビッド ジェイ． リビングストン，
フィリップ ランバート，
カール ディー． ノーミントン，
ピーター エリオット，
Original Assignee
サートリス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サートリス ファーマシューティカルズ， インコーポレイテッド filed Critical サートリス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2008542296A publication Critical patent/JP2008542296A/ja
Publication of JP2008542296A5 publication Critical patent/JP2008542296A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2008513752A 2005-05-25 2006-05-24 サーチュイン活性化剤による眼障害の処置 Pending JP2008542296A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68425205P 2005-05-25 2005-05-25
US73155005P 2005-10-28 2005-10-28
US78835806P 2006-03-30 2006-03-30
PCT/US2006/020406 WO2006127987A2 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators

Publications (2)

Publication Number Publication Date
JP2008542296A true JP2008542296A (ja) 2008-11-27
JP2008542296A5 JP2008542296A5 (enExample) 2009-06-18

Family

ID=37307152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008513752A Pending JP2008542296A (ja) 2005-05-25 2006-05-24 サーチュイン活性化剤による眼障害の処置

Country Status (5)

Country Link
EP (1) EP1928440A2 (enExample)
JP (1) JP2008542296A (enExample)
AU (1) AU2006249816A1 (enExample)
CA (1) CA2609549A1 (enExample)
WO (1) WO2006127987A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516834A (ja) * 2009-02-04 2012-07-26 ディーエスエム アイピー アセッツ ビー．ブイ． レスベラトロール組成物
JP2014101313A (ja) * 2012-11-20 2014-06-05 Toyo Shinyaku Co Ltd 皮膚外用剤
WO2018052019A1 (ja) * 2016-09-13 2018-03-22 めぐみ 田中 視覚機能改善剤及び視覚機能の改善方法
JPWO2018030389A1 (ja) * 2016-08-08 2019-06-13 学校法人慶應義塾 Ｎａｄ関連代謝産物の利用
JP2019534335A (ja) * 2016-11-14 2019-11-28 ミングゥ・ワン 眼表面疾患の治療のための製剤および関連方法
JPWO2020262497A1 (enExample) * 2019-06-25 2020-12-30
RU2822512C2 (ru) * 2019-06-25 2024-07-08 Сэндзю Фармасьютикал Ко., Лтд. Новое применение никотинамид мононуклетида (nmn) и никотинамид рибозида (nr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
WO2009089011A2 (en) * 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
BRPI0912356A2 (pt) 2008-05-01 2015-10-06 Sirtris Pharmaceuticals Inc compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso
CA2729128C (en) 2008-07-03 2016-05-31 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
WO2010037129A1 (en) 2008-09-29 2010-04-01 Sirtris Pharmaceuticals Inc. Quinazolinone, quinolone and related analogs as sirtuin modulators
GB0903688D0 (en) * 2009-03-03 2009-04-15 Agentis Suppliments Composition
CA2779303A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
PL2968306T3 (pl) 2013-03-15 2024-01-29 Washington University Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US20160374908A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Skin care composition and methods of using the same
US20160374918A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
US9833398B2 (en) 2016-01-11 2017-12-05 The Procter & Gamble Company Method of treating a skin condition and compositions therefor
LT3416654T (lt) 2016-02-18 2022-01-10 Invirsa, Inc. 5’-adenozindifosfato ribozės (adpr) medicininis panaudojimas
CA3055755A1 (en) * 2017-03-07 2018-09-13 Cempra Pharmaceuticals, Inc. Compositions and methods for treating dry eye diseases
CN110785161B (zh) 2017-06-23 2023-06-20 宝洁公司 用于改善皮肤外观的组合物和方法
ES2949441T3 (es) 2018-03-27 2023-09-28 Invirsa Inc Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR)
EP3817717A1 (en) 2018-07-03 2021-05-12 The Procter & Gamble Company Method of treating a skin condition
US11583488B2 (en) 2020-06-01 2023-02-21 The Procter & Gamble Company Method of improving penetration of a vitamin B3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062406A1 (es) * 2002-01-24 2003-07-31 Universidad De Alicante Procedimiento para la produccion de resveratrol en cultivos celulares
JP2003252760A (ja) * 2002-03-01 2003-09-10 Mitsubishi Pharma Corp 網膜疾患治療剤および／または予防剤
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
WO2005034960A1 (en) * 2003-10-10 2005-04-21 Resverlogix Corp. Treatment of diseases associated with the egr-1 enhancer element
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
JP2008538215A (ja) * 2005-03-30 2008-10-16 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性化剤による眼障害の処置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
EP0398925B1 (en) * 1988-01-19 1993-10-20 Children's Hospital Corporation Growth inhibiting agent and the use thereof
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
CA2350396C (en) * 1998-12-24 2010-06-29 1333366 Ontario Inc. A composition useful to treat periodontal disease
JP2000344622A (ja) * 1999-03-31 2000-12-12 Sunstar Inc スチルベン系化合物及びそれを含有する植物抽出物の安定化およびスチルベン系化合物及びそれを含有する植物抽出物を安定配合した食品、医薬品、化粧品、口腔製剤
CA2312505A1 (en) * 2000-06-27 2001-12-27 1333366 Ontario Inc. Resveratrol compositions for topical use in the treatment of oral diseases and infections
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
CN1220486C (zh) * 2002-11-15 2005-09-28 董英杰 白藜芦醇类化合物的β－环糊精或其衍生物的包合物及其制备方法
JP4564920B2 (ja) * 2003-04-18 2010-10-20 株式会社最先端医学研究所 眼に適用する疾患治療剤
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DE102004002787A1 (de) * 2004-01-19 2005-08-11 Merck Patent Gmbh Flavonoid-Komplexe

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062406A1 (es) * 2002-01-24 2003-07-31 Universidad De Alicante Procedimiento para la produccion de resveratrol en cultivos celulares
JP2003252760A (ja) * 2002-03-01 2003-09-10 Mitsubishi Pharma Corp 網膜疾患治療剤および／または予防剤
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
WO2005034960A1 (en) * 2003-10-10 2005-04-21 Resverlogix Corp. Treatment of diseases associated with the egr-1 enhancer element
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
JP2008538215A (ja) * 2005-03-30 2008-10-16 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性化剤による眼障害の処置

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CSNC200900720004; 医学のあゆみ Ｖｏｌ．１９５, 2000, ｐｐ．７８５-８ *
JPN6011067213; Ｊ　Ｐｈａｒｍａｃｏｌ　Ｅｘｐ　Ｔｈｅｒ Ｖｏｌ．３０２, 2002, ｐｐ．３６９-７３ *
JPN6011067219; Ｊ　Ｌｅｕｋｏｃ　Ｂｉｏｌ Ｖｏｌ．７５, 2004, ｐｐ．９３９-５０ *
JPN6011067222; Ｃｈｅｍ　Ｂｉｏｌ　Ｉｎｔｅｒａｃｔ Ｖｏｌ．１５１, 2004, ｐｐ．１４３-９ *
JPN6012043262; 医学のあゆみ Ｖｏｌ．１９５, 2000, ｐｐ．７８５-８ *
JPN6012043264; Ｃｕｒｒ　Ｏｐｉｎ　Ｃｈｅｍ　Ｂｉｏｌ Ｖｏｌ．９, 20050824, ｐｐ．４３１-４０ *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516834A (ja) * 2009-02-04 2012-07-26 ディーエスエム アイピー アセッツ ビー．ブイ． レスベラトロール組成物
US8927046B2 (en) 2009-02-04 2015-01-06 Dsm Ip Assets B.V. Resveratrol compositions
JP2014101313A (ja) * 2012-11-20 2014-06-05 Toyo Shinyaku Co Ltd 皮膚外用剤
JP7090336B2 (ja) 2016-08-08 2022-06-24 慶應義塾 Ｎａｄ関連代謝産物の利用
JPWO2018030389A1 (ja) * 2016-08-08 2019-06-13 学校法人慶應義塾 Ｎａｄ関連代謝産物の利用
US10898738B2 (en) 2016-09-13 2021-01-26 Megumi Tanaka Visual function printing agent, and method for improving visual functions
JPWO2018052019A1 (ja) * 2016-09-13 2019-06-24 めぐみ 田中 視覚機能改善剤及び視覚機能の改善方法
WO2018052019A1 (ja) * 2016-09-13 2018-03-22 めぐみ 田中 視覚機能改善剤及び視覚機能の改善方法
JP2019534335A (ja) * 2016-11-14 2019-11-28 ミングゥ・ワン 眼表面疾患の治療のための製剤および関連方法
JPWO2020262497A1 (enExample) * 2019-06-25 2020-12-30
WO2020262497A1 (ja) * 2019-06-25 2020-12-30 千寿製薬株式会社 ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途
RU2822512C2 (ru) * 2019-06-25 2024-07-08 Сэндзю Фармасьютикал Ко., Лтд. Новое применение никотинамид мононуклетида (nmn) и никотинамид рибозида (nr)
JP7572007B2 (ja) 2019-06-25 2024-10-23 千寿製薬株式会社 ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途

Also Published As

Publication number Publication date
EP1928440A2 (en) 2008-06-11
WO2006127987A3 (en) 2008-04-17
AU2006249816A1 (en) 2006-11-30
CA2609549A1 (en) 2006-11-30
WO2006127987A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
AU2006230478B2 (en) Treatment of eye disorders with sirtuin modulators
JP2008542296A (ja) サーチュイン活性化剤による眼障害の処置
US20060292099A1 (en) Treatment of eye disorders with sirtuin modulators
JP7455917B2 (ja) 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
TWI709410B (zh) 具有生物活性親脂性化合物之聚乙二醇化脂質奈米粒子
KR20060127043A (ko) 녹내장성 망막병증 및 시각신경병증의 치료용 약제
Sharma et al. Application of Vitamin E TPGS in ocular therapeutics–Attributes beyond excipient
RU2726193C2 (ru) Наноструктурированные композиции для доставки силибинина и других активных ингредиентов для лечения глазных заболеваний
EP2170343A1 (en) Treatment of age-related macular degeneration
JP2024534403A (ja) 眼疾患のための緑茶ベースのナノコンプレックス
Cetin A review on ophthalmic delivery systems containing flavonoids for the treatment of eye diseases
Alaimo et al. Chitosan-based nanosuspensions for ocular diagnosis and therapy
JP5087242B2 (ja) ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム
HK40097477A (en) Preparation of cyclodextrin nanoparticle for ophthalmic drug delivery
US20230405024A1 (en) Novel nano-formulation of cannabidiol (cbd) and other cannabinoids for treatment of ocular disorders
HK40041547A (en) Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases
JP2007056012A (ja) 軟膏様組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130130